Risk of developing hyperkalemia in patients with hypertension treated with combination antihypertensive therapy - a retrospective register-based study.

IF 4.3 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Hypertension Research Pub Date : 2024-10-31 DOI:10.1038/s41440-024-01894-2
Fatma Luai Mahdi Al-Janabi, Fatme Moussa, Sarah Taleb, Peter Derek Christian Leutscher, Marc Meller Søndergaard, Dorte Melgaard, Peter Søgaard, Christian Torp-Pedersen, Kristian Kragholm, Maria Lukács Krogager
{"title":"Risk of developing hyperkalemia in patients with hypertension treated with combination antihypertensive therapy - a retrospective register-based study.","authors":"Fatma Luai Mahdi Al-Janabi, Fatme Moussa, Sarah Taleb, Peter Derek Christian Leutscher, Marc Meller Søndergaard, Dorte Melgaard, Peter Søgaard, Christian Torp-Pedersen, Kristian Kragholm, Maria Lukács Krogager","doi":"10.1038/s41440-024-01894-2","DOIUrl":null,"url":null,"abstract":"<p><p>The risk of hyperkalemia in relation to different combinations of antihypertensive therapy remains to be elucidated. In this Danish register-based study, we aimed to investigate the risk of developing hyperkalemia in relation to different combinations of antihypertensive therapy. Using incidence density matching, we matched a hyperkalemic patient to five normokalemic patients on eGFR groups, age, sex, and time between study entry and date of potassium measurement. Combination therapies were subdivided into eight groups: beta blockers (BB) + calcium channel blockers (CCB), BB + renin angiotensin system inhibitors (RASi), BB + RASi + mineralocorticoid receptor antagonists (MRA), CCB + RASi, CCB + RASi + thiazides, CCB + thiazides, RASi + thiazides, and other combinations. Multivariable conditional logistic regression was used to estimate the odds of hyperkalemia within 90 days for each of the eight antihypertensive combination therapies. A total of 793 patients with hyperkalemia were matched to 3598 normokalemic patients. In multivariable analysis, odds of developing hyperkalemia when being treated with BB + RASi + MRA was 1.95 (95% CI, 1.39-2.72) compared to RASi + thiazides (reference). CCB + thiazides (OR, 0.76 [95% CI, 0.45-1.28]) and CCB + RASi + Thiazid (OR 0.81 [95% CI, 0.51-1.28]) were among the others not significantly associated with hyperkalemia. Combinations of BB + RASi + MRA were significantly associated with an increased risk of developing hyperkalemia within 90 days of initiating treatment. Patients treated with BB + RASi + MRA within 90 days of treatment initiation, were associated with an increased hyperkalemia risk. When treating hypertensive patients with combination antihypertensive therapy, identifying and monitoring patients with a high risk of dyskalemias is a crucial goal to avoid serious adverse effects and detrimental outcomes related to dyskalemia.</p>","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hypertension Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41440-024-01894-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

The risk of hyperkalemia in relation to different combinations of antihypertensive therapy remains to be elucidated. In this Danish register-based study, we aimed to investigate the risk of developing hyperkalemia in relation to different combinations of antihypertensive therapy. Using incidence density matching, we matched a hyperkalemic patient to five normokalemic patients on eGFR groups, age, sex, and time between study entry and date of potassium measurement. Combination therapies were subdivided into eight groups: beta blockers (BB) + calcium channel blockers (CCB), BB + renin angiotensin system inhibitors (RASi), BB + RASi + mineralocorticoid receptor antagonists (MRA), CCB + RASi, CCB + RASi + thiazides, CCB + thiazides, RASi + thiazides, and other combinations. Multivariable conditional logistic regression was used to estimate the odds of hyperkalemia within 90 days for each of the eight antihypertensive combination therapies. A total of 793 patients with hyperkalemia were matched to 3598 normokalemic patients. In multivariable analysis, odds of developing hyperkalemia when being treated with BB + RASi + MRA was 1.95 (95% CI, 1.39-2.72) compared to RASi + thiazides (reference). CCB + thiazides (OR, 0.76 [95% CI, 0.45-1.28]) and CCB + RASi + Thiazid (OR 0.81 [95% CI, 0.51-1.28]) were among the others not significantly associated with hyperkalemia. Combinations of BB + RASi + MRA were significantly associated with an increased risk of developing hyperkalemia within 90 days of initiating treatment. Patients treated with BB + RASi + MRA within 90 days of treatment initiation, were associated with an increased hyperkalemia risk. When treating hypertensive patients with combination antihypertensive therapy, identifying and monitoring patients with a high risk of dyskalemias is a crucial goal to avoid serious adverse effects and detrimental outcomes related to dyskalemia.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
接受联合降压治疗的高血压患者罹患高钾血症的风险--一项基于登记簿的回顾性研究。
不同降压疗法组合的高钾血症风险仍有待阐明。在这项基于丹麦登记册的研究中,我们旨在调查不同降压疗法组合导致高钾血症的风险。通过发病率密度匹配,我们将一名高钾血症患者与五名正常血钾患者的 eGFR 组别、年龄、性别以及进入研究和血钾测量日期之间的时间进行了匹配。联合疗法被细分为八组:β受体阻滞剂(BB)+钙通道阻滞剂(CCB)、BB+肾素血管紧张素系统抑制剂(RASi)、BB+RASi+促矿物质皮质激素受体拮抗剂(MRA)、CCB+RASi、CCB+RASi+噻嗪类药物、CCB+噻嗪类药物、RASi+噻嗪类药物以及其他联合疗法。多变量条件逻辑回归用于估算八种降压联合疗法中每种疗法在 90 天内发生高钾血症的几率。共有 793 名高钾血症患者与 3598 名正常血钾患者进行了配对。在多变量分析中,与 RASi + 噻嗪类药物(参考值)相比,使用 BB + RASi + MRA 治疗时发生高钾血症的几率为 1.95(95% CI,1.39-2.72)。CCB + 噻嗪类药物(OR,0.76 [95% CI,0.45-1.28])和 CCB + RASi + 噻嗪类药物(OR,0.81 [95% CI,0.51-1.28])与高钾血症无显著相关性。BB+RASi+MRA组合与开始治疗后90天内发生高钾血症的风险增加有显著相关性。开始治疗后 90 天内接受 BB + RASi + MRA 治疗的患者患高钾血症的风险增加。在对高血压患者进行联合降压治疗时,识别和监测高钾血症风险患者是避免与高钾血症相关的严重不良反应和不利结果的关键目标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hypertension Research
Hypertension Research 医学-外周血管病
CiteScore
7.40
自引率
16.70%
发文量
249
审稿时长
3-8 weeks
期刊介绍: Hypertension Research is the official publication of the Japanese Society of Hypertension. The journal publishes papers reporting original clinical and experimental research that contribute to the advancement of knowledge in the field of hypertension and related cardiovascular diseases. The journal publishes Review Articles, Articles, Correspondence and Comments.
期刊最新文献
Asian hypertensive population: key insights from large-scale data analysis Association between urinary cotinine level and hypertensive disorders of pregnancy in women with uterine myoma: findings from the Japan Environment and Children's Study. Differences in the effects of exercise on blood pressure depending on the physical condition of the subject and the type of exercise: a systematic review and meta-analysis. Risk of developing hyperkalemia in patients with hypertension treated with combination antihypertensive therapy - a retrospective register-based study. Prevention of atherosclerotic cerebro-cardiovascular disease: a key objective in blood pressure management for coronary artery disease in East Asia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1